Serelaxin – neuer medikamentöser Ansatz bei akuter Herzinsuffizienz

Abstract

With approximately 400 000 patients per year acute heart failure is among the most frequent reasons for hospitalization in Germany. In-hospital mortality reaches up to 10 % and up to 30 % over the first six months after discharge. According to the current (update 2012) guidelines of the European Society of Cardiology (ESC) two major forms of acute heart failure can be differentiated, namely (I) with pulmonary congestion/oedema without shock, and (II) with hypotension, hypoperfusion and shock, which require a specific therapeutic regimen (diuretics and vasodilators vs. inotropes). Innovative approaches to treat acute heart failure with the adenosine antagonist rolofylline, the B-type natriuretic peptide nesiritide, the endothelin antagonist tezosentan, and the vasopressin antagonist tolvaptan did not meet the expectations. In contrast, in patients with pulmonary congestion and a systolic blood pressure > 125 mmHg a 48-hr infusion of serelaxin was shown to improve dyspnea (visual analogue scale, but not Likert scale), to shorten length of hospitalization, and to reduce 6-month mortality in the RELAX-AHF study. However, rehospitalization for heart failure or renal failure over the first 60 days was not reduced by serelaxin. Serelaxin is a vasodilator, that has antiinflammatory and antifibrotic properties, improves renal function, and stimulates angiogenesis. Thus, serelaxin has several properties which may explain the persistent effect after a 48-hr infusion. However, a large scale trial is required to prove that the prognostic effect of serelaxin is reproducable and that serelaxin is superior to the currently used therapeutic regimen with high doses of vasodilators (nitrate or nitroprusside). Provided that a clear superiority of serelaxin will be shown in such a trial, this new therapeutic approach should not be witheld to those patients, who fulfill the clinical requirements.

• Literatur

• 1 O’Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to initiate Livesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-673
• 2 McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869
• 3 Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide nitrate in severe pulmonary oedema. Lancet 1998; 351: 389-393
• 4 O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43
• 5 Massie BM, O´Connor CM, Metra M et al. Rolofylline, an adenosine A1-receptor antagonist, in heart failure. N Engl J Med 2010; 363: 1419-1428
• 6 McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-2019
• 7 Konstam MA, Gherghiade M, Burnett Jr JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331
• 8 Gheorghiade M, Konstam MA, Burnett Jr JC et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trial. JAMA 2007; 297: 1332-1343
• 9 Teichman SL, Unemori E, Teerlink JR et al. Relaxin: Review of biology and potential role in heart failure. Curr Heart Fail Rep 2010; 7: 75-82
• 10 Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicenter, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439
• 11 Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial. Lancet 2013; 381: 196-206
• 12 Metra M, Cotter G, Davidson BA et al. Effect of Serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206